These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 29562511)

  • 21. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
    Ruthirakuhan M; Herrmann N; Suridjan I; Abraham EH; Farber I; Lanctôt KL
    Expert Opin Pharmacother; 2016 Dec; 17(18):2417-2429. PubMed ID: 27825018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alzheimer's disease drug development pipeline: 2018.
    Cummings J; Lee G; Ritter A; Zhong K
    Alzheimers Dement (N Y); 2018; 4():195-214. PubMed ID: 29955663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders.
    Vissers MFJM; Heuberger JAAC; Groeneveld GJ
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alzheimer's disease clinical trial update 2019-2021.
    Pleen J; Townley R
    J Neurol; 2022 Feb; 269(2):1038-1051. PubMed ID: 34609602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alzheimer's disease drug development pipeline: 2022.
    Cummings J; Lee G; Nahed P; Kambar MEZN; Zhong K; Fonseca J; Taghva K
    Alzheimers Dement (N Y); 2022; 8(1):e12295. PubMed ID: 35516416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cognitively Healthy Individuals Want to Know Their Risk for Alzheimer's Disease: What Should We Do?
    Stites SD
    J Alzheimers Dis; 2018; 62(2):499-502. PubMed ID: 29480203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020.
    Hampel H; Lista S; Teipel SJ; Garaci F; Nisticò R; Blennow K; Zetterberg H; Bertram L; Duyckaerts C; Bakardjian H; Drzezga A; Colliot O; Epelbaum S; Broich K; Lehéricy S; Brice A; Khachaturian ZS; Aisen PS; Dubois B
    Biochem Pharmacol; 2014 Apr; 88(4):426-49. PubMed ID: 24275164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of Biomarkers in Alzheimer's Disease Drug Development.
    Cummings J
    Adv Exp Med Biol; 2019; 1118():29-61. PubMed ID: 30747416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacotherapies for sleep disturbances in Alzheimer's disease.
    McCleery J; Cohen DA; Sharpley AL
    Cochrane Database Syst Rev; 2014 Mar; (3):CD009178. PubMed ID: 24659320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacotherapy for Alzheimer's disease: what's new on the horizon?
    Khoury R; Gallop A; Roberts K; Grysman N; Lu J; Grossberg GT
    Expert Opin Pharmacother; 2022 Aug; 23(11):1305-1323. PubMed ID: 35793398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Registries to Boost the Clinical Trials for the Disease Modifying Therapy of Alzheimer's Disease].
    Akiyama H
    Brain Nerve; 2017 Jul; 69(7):743-748. PubMed ID: 28739987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.
    Budd Haeberlein S; O'Gorman J; Chiao P; Bussière T; von Rosenstiel P; Tian Y; Zhu Y; von Hehn C; Gheuens S; Skordos L; Chen T; Sandrock A
    J Prev Alzheimers Dis; 2017; 4(4):255-263. PubMed ID: 29181491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer drugs with high repositioning potential for Alzheimer's disease.
    Majeed J; Sabbagh MN; Kang MH; Lawrence JJ; Pruitt K; Bacus S; Reyna E; Brown M; Decourt B
    Expert Opin Emerg Drugs; 2023 Dec; 28(4):311-332. PubMed ID: 38100555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lessons learned from failed and discontinued clinical trials for the treatment of Alzheimer's disease: future directions.
    Carlsson CM
    J Alzheimers Dis; 2008 Oct; 15(2):327-38. PubMed ID: 18953117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New and emerging treatments for Alzheimer's disease.
    Corbett A; Smith J; Ballard C
    Expert Rev Neurother; 2012 May; 12(5):535-43. PubMed ID: 22550982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of Alzheimer's Disease: Lessons Learned and Applied.
    Galvin JE
    J Am Geriatr Soc; 2017 Oct; 65(10):2128-2133. PubMed ID: 28766695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study.
    Burnham SC; Raghavan N; Wilson W; Baker D; Ropacki MT; Novak G; Ames D; Ellis K; Martins RN; Maruff P; Masters CL; Romano G; Rowe CC; Savage G; Macaulay SL; Narayan VA; ;
    J Alzheimers Dis; 2015; 46(4):1079-89. PubMed ID: 26402634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions.
    Elmaleh DR; Farlow MR; Conti PS; Tompkins RG; Kundakovic L; Tanzi RE
    J Alzheimers Dis; 2019; 71(3):715-732. PubMed ID: 31476157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early-stage Alzheimer disease: getting trial-ready.
    Aisen PS; Jimenez-Maggiora GA; Rafii MS; Walter S; Raman R
    Nat Rev Neurol; 2022 Jul; 18(7):389-399. PubMed ID: 35379951
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.